Scientists have revealed that an anti-obesity drug changes the way the brain responds to appetizing, high-calorie foods in obese individuals. This insight may aid the development of new anti-obesity drugs which reduce the activity in the regions of the brain stimulated by the sight of tasty foods. This is not unexpected since the brain is the center of many such sensory responses. For example in 2008, researchers at Tufts University School of Medicine and colleagues demonstrated a link between a predisposition to obesity and defective dopamine signaling in the mesolimbic system in rats. The new study at the University of Cambridge discovered that the anti-obesity drug sibutramine reduced brain responses in two regions of the brain, the hypothalamus and the amygdala, both of which are known to be important in appetite control and eating behavior. Their findings are reported today in The Journal of Neuroscienc